Examples of conditions the drug may be used for
include lymphocytic leukemia, multiple myeloma, glomerulonephritis, non-erosive arthritis, immune - mediated skin disease, feline pemphigus foliaceous and severe feline eosinophilic granuloma complex.
Not exact matches
Using a novel technique to genetically modify T cells for adoptive transfer, Carl June, Michael Kalos, David Porter, Bruce Levine, and colleagues at the University of Pennsylvania School of Medicine achieve clinical responses in patients with chronic
lymphocytic leukemia,
including two complete, durable (one year) clinical responses, accompanied by in vivo expansion and long - term functional persistence of gene - modified cells.
Ibrutinib is also approved to treat chronic
lymphocytic leukemia / small
lymphocytic lymphoma,
including patients with 17p deletion, mantle cell lymphoma after at least one prior therapy, and patients with Waldenstrom macroglobulinemia.
In 2011, Carl H. June, M.D. (a CRI clinical investigator and member of the CRI Scientific Advisory Council), Michael Kalos, Ph.D. (a former CRI postdoctoral fellow and member of the CRI Scientific Advisory Council), and colleagues at the University of Pennsylvania School of Medicine achieved good clinical responses in patients with chronic
lymphocytic leukemia (CLL),
including two complete, durable clinical responses.
ONC201 demonstrated (GI50 1 - 8 µM) dose - and time - dependent efficacy in acute myeloid
leukemia (AML), acute lymphoblastic
leukemia (ALL), chronic myelogenous
leukemia (CML), chronic
lymphocytic leukemia (CLL), diffuse large B - cell lymphoma (DLBCL), mantle cell lymphoma (MCL), Burkitt's lymphoma, anaplastic large cell lymphoma (ALCL), cutaneous T - cell lymphoma (CTCL), Hodgkin's lymphoma (nodular sclerosis) and multiple myeloma (MM) cell lines
including cells resistant to standard of care (dexamethasone in MM) and primary samples.
B - cell chronic
lymphocytic leukemia (B - CLL) is a common cancer in dogs, but little is known about the disease,
including its clinical progression and survival expectations for patients.